Hookipa Pharma (NASDAQ:HOOK) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a research note issued to investors on Monday, Benzinga reports. The firm currently has a $5.00 price target on the stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $6.50 price objective on shares of Hookipa Pharma in a research report on Monday.

Hookipa Pharma Stock Performance

NASDAQ:HOOK opened at $0.72 on Monday. The firm has a 50-day moving average price of $0.70 and a two-hundred day moving average price of $0.63. Hookipa Pharma has a 52 week low of $0.41 and a 52 week high of $2.05. The firm has a market cap of $60.48 million, a price-to-earnings ratio of -0.82 and a beta of 1.03.

Institutional Investors Weigh In On Hookipa Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Hookipa Pharma by 16.4% during the 4th quarter. Vanguard Group Inc. now owns 2,114,802 shares of the company’s stock worth $1,713,000 after purchasing an additional 297,310 shares in the last quarter. CHI Advisors LLC purchased a new position in shares of Hookipa Pharma during the second quarter worth about $694,000. Knoll Capital Management LLC grew its stake in Hookipa Pharma by 1,739.1% in the 2nd quarter. Knoll Capital Management LLC now owns 5,517,385 shares of the company’s stock worth $4,855,000 after buying an additional 5,217,385 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Hookipa Pharma during the 2nd quarter worth $1,008,000. Finally, XTX Topco Ltd bought a new stake in Hookipa Pharma during the second quarter worth about $298,000. Institutional investors own 63.88% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.